⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Bioxodes and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Bioxodes
↗Gosselies, Belgium
Bioxodes is a clinical-stage biopharmaceutical company based in Gosselies, Belgium, focused on developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. The company leverages a deep understanding of thrombo-inflammatory processes to design innovative product candidates, with a primary focus on addressing unmet medical needs in stroke management.
The company's lead asset, BIOX-101, is a first-in-class recombinant protein derived from tick saliva (Ixodes ricinus). It features a unique dual mechanism of action that inhibits both coagulation factors (FXIa and FXIIa) and neutrophil activation, providing antithrombotic and anti-inflammatory benefits without increasing bleeding risk. Bioxodes is currently advancing BIOX-101 through clinical development for intracerebral hemorrhage (ICH) and ischemic stroke.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$40M
Investors:Newton Biocapital, Sfpi-Fpim, Financière spin-off Luxembourgeoise, Sambrinvest, LSRP - Life Sciences Research Partners
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2a completed; Phase 2b/3 planning
Modalities:Recombinant protein
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Walloon Region (SPW Recherche) - Research support
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Marc Dechamps - CEO
Philippe Monteyne - Chairman
LINKS
Website:bioxodes.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Bioxodes. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.